A Phase II Study of Benralizumab in People with Rash or Itching Caused by Immunotherapies or Targeted Cancer Treatments

Share
Print

Full Title

Phase II Study of IL-5-receptor-alpha-chain (IL-5Ra) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients

Purpose

The purpose of this study is to assess the safety and effectiveness of the drug benralizumab in people who develop rashes or itching as a result of immunotherapy or targeted cancer treatments. Cancer therapies may result in rash or itching, which are frequently associated with a type of white blood cell called eosinophils. Eosinophils are part of the immune system; they fight some infections, but very high levels of eosinophils can cause inflammation that may damage the skin. They are especially involved in allergies, rashes, or itching resulting from certain medications.

Benralizumab is used to reduce high levels of eosinophils in people with asthma; its use in this study is investigational. It is hoped that benralizumab can reduce rashes caused by cancer treatments by reducing the level of eosinophils in the blood, decreasing the need for steroids, improving patients’ quality of life, and allowing them to continue to receive their usual cancer treatment. Benralizumab is given as an injection into the skin once a month.

Eligibility

This study is for patients age 18-85 who are experiencing rash or itching as a result of immunotherapy or targeted therapy for cancer and high levels of eosinophils in the blood.

For more information about this study, please contact Dr. Mario Lacouture at 646-608-2337 or lacoutum@mskcc.org.

Protocol

20-344

Phase

II

Investigator